15.04.2024 News

Next boost for Corporate/M&A practice: Regina Engelstädter joins Oppenhoff in Frankfurt

Oppenhoff boosts its Corporate/M&A practice with the next partner addition within a few weeks: Dr Regina Engelstädter joined from Paul Hastings as of April 15, 2024, and works in Oppenhoff's Frankfurt office. In early March, Dr. Barnim von den Steinen had joined the Oppenhoff office in Frankfurt.

Regina Engelstädter started her career at Baker McKenzie, became a partner there, and later moved on to Paul Hastings. She focuses on M&A, corporate law, joint ventures, and corporate restructuring. She primarily advises on complex domestic and cross-border transactions. Additionally, she works as a notary. She was amongst others advising Fujian Grand Chip Investment Fund LP in the intended acquisition of AIXTRON SE, Nexter Systems S.A. in forming a joint venture with Krauss-Maffei Wegmann GmbH & Co. KG to establish a leading European military land systems manufacturer from France and Germany, the Publicis Group in the acquisition of media agencies AKM3 and AKOM360 GmbH, Shanghai Fosun Pharmaceutical in entering a strategic alliance with BioNTech SE for the development and distribution of a COVID-19 vaccine and Schott AG in the sale of Schott Medica GmbH. The latter transaction was awarded "Finance Top Deal of the Year 2022." Regina Engelstädter is frequently recommended as a lawyer for M&A and private equity in various legal directories.

Managing Partner Myriam Baars-Schilling: "We are very pleased to take in Regina a highly experienced M&A lawyer with an impressive track record on. With her, we can further expand our growing business in complex, cross-border transactions."

Regina Engelstädter: "I am very much looking forward to join forces with the ambitious Oppenhoff team. The firm, with its reputation, international network and outstanding full-service, is a top place to advise existing clients and attract new ones."

Oppenhoff's Corporate/M&A team of around 40 lawyers advises on various matters including traditional investments and new equity models, corporate and governance structures, corporate succession, and corporate legal disputes. Oppenhoff recently advised KNDS on their cornerstone investment in the RENK Group's IPO, tesa SE on the acquisition of tesa Labtec GmbH by Adhex Pharma, the Austrian Federal Railways ÖBB on the purchase of Go-Ahead Deutschland, Hawesko SE on their investment in the Baltic Dunker Group and the seller of the Galileo Food Group to Dr. Oetker.

Back to list

Myriam Baars-Schilling

Myriam Baars-Schilling


Konrad-Adenauer-Ufer 23
50668 Cologne
T +49 221 2091 210
M +49 172 3460 632